GPX4 and cancer: Thus, the lack of suitable in vivo GPX4 inhibitors and the predicted systemic toxicity of such compounds (Friedmann Angeli et al, 2014; Brutsch et al, 2015; Carlson et al, 2016) limit the translation of these discoveries into cancer therapies.